Overcome drawbacks of working with commonly used serotypes Ad5 and Ad2 with Ad19a/64
Now, there is a an alternative available to Ad5 and Ad2:
Ad19a/64, the first openly accessible subtype D adenovirus -
Not only does it transduce human-derived cells (myoblasts and myotubes) more efficiently when compared to Ad5, it also possesses CAR independent binding properties, targeting a sialic acid-dependent receptor
Ad19a/64 helps you
- targeting new cell types/tissue due to its unique receptor affinities with the added benefit of
- realizing low pre-immunization rates within the human population
Whenever you experience with Ad5
- limitations due to CAR dependant transduction or
pre-existing anti-adenovirus immunity against in Ad5 in humans
contact SIRION Biotech for its unique Ad19a/64-BAC-technology. SIRION Biotech is actively seeking strategic alliances for the development of commercial use of Ad19a/64(see below for the Open Innovation Intiative).The offered material is license-free for research only, any and all other uses require an explicit approval from Sirion Biotech GmbH.
Transduction of myoblasts with Ad5-EGFP (Ad5) and Ad19a/64-EGFP (Ad19a). Primary myoblasts of human, ape, pig and mouse origin were transduced with 1250 VP/cell (open columns). 2500 VP/cell (shaded columns) and 12500 VP/cell (solid columns), respectively, and GFP expression was quantified after 48 hr. Each value represents the mean of transgene expression per well in relative light units (RLU) from five independent experiments +/- SD.
Transduction of primary myotubes (MTs) with Ad5EGFP and Ad19a/64-EGFP. Ten-day-old myotubes were transduced with 1250 VP/cell (open columns). 2500 VP/cell (shaded columns) and 12500 VP/cell (solid columns), respectively. GFP expression was quantified after 48 hr. Each value represents the mean relative light units (RLU) of five independent transductions +/- SD.